BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rebelo R, Polónia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 2021;14:280. [PMID: 33804613 DOI: 10.3390/ph14030280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang CY, Liu S, Yang M. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options. World J Gastroenterol 2022; 28(48): 6827-6845 [DOI: 10.3748/wjg.v28.i48.6827] [Reference Citation Analysis]
2 Ali A, Chianese U, Papulino C, Toraldo A, Abakar MEA, Passaro E, Cennamo R, Del Gaudio N, Altucci L, Benedetti R. Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:3799. [DOI: 10.3390/cancers14153799] [Reference Citation Analysis]
3 Branco H, Oliveira J, Antunes C, Santos LL, Vasconcelos MH, Xavier CPR. Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin. Int J Mol Sci 2022;23. [PMID: 35408988 DOI: 10.3390/ijms23073631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Anaya-Ruiz M, Perez-Santos M. Drug repurposing of adapalene for melanoma treatment. Pharm Pat Anal 2022. [PMID: 35168402 DOI: 10.4155/ppa-2021-0021] [Reference Citation Analysis]